Adam Bluestein

Selected Work

“Ozempic for Everyone? Inside Novo Nordisk’s Big Plans for Its Weight-Loss Drugs.” How the Danish diabetes specialist shifted gears and targeted the U.S. market with its GLP-1 blockbusters. Fast Company, December 2023

“Moderna became a hero with its COVID-19 vaccine—now comes the hard part.”
Profile of pandemic darling and mRNA pioneer and its efforts to deliver new treatments. Fast Company, June 2023

“How a microwave-sized device could make personalized cancer treatment more accessible.” Can legendary former J&J CSO Paul Stoffels transform Belgian biotech Galapagos into a CAR-T powerhouse?  Fast Company,  April 2023 

“The Lock-Picker, the Lockmaker, and the Odyssey to Expose a Major Security Flaw.”
Ethical hackers take on the security industry. Bloomberg Businessweek, December 2021

“What Is It Really Like to Take Your Company Public via a SPAC?” A behind-the-scenes look at how Ginkgo Bioworks scored the biggest biotech IPO ever.  Fortune Quarterly Investment Guide, Q3 2021

How Mormons Built the Next Silicon Valley While No One Was Looking.” LDS religious values infuse Utah’s  blazing-hot tech scene. As businesses seek to lure outsiders, does that need to change? Marker, January 2020

“Flower Power.” How Mikey Steinmetz, CEO and cofounder of craft-grown cannabis distributor Flow Kana, is helping multi-generation Emerald Triangle growers weather the storms of legalization. Men’s Journal, January/February 2020

“After a Comeback, 23andMe Faces Its Next Test.” Profile of Anne Wojcicki, CEO of the pioneering consumer genomics company. Fast Company, September 2017